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Abstract
Autism spectrum disorder (ASD) is thought to result from a combination of
genetic and environmental factors, yet a specific cause remains unknown. In this study,
exposure and outcome data from a South Korean cohort (N=3,711) were analyzed to
investigate the possibility of an environmental contribution to autism etiology. No
significant association was observed between use of prenatal medications and autistic
behaviors, as measured by Korean versions of both the Autism Spectrum Screening
Questionnaire (ASSQ; OR 1.20, 95% CI 0.95–1.51) and the Social Responsiveness Scale
(SRS; OR 0.98, 95% CI 0.78–1.25). Similarly, no significant associations were observed
when use of prenatal vitamins, folic acid, or iron supplements was examined. There was
also no dose-response relationship observed between number of medications taken during
pregnancy and increased autistic behaviors. No evidence for a role of prenatal medication
use in autism etiology is suggested by the data in this study. Future investigations
focusing on specific subgroups of medications in this population are warranted.
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Tables
Table 1. Characteristics of study participants according to prenatal medication status.
Exposure statusa
Took any prenatal
medication
Did not take any prenatal
b
Characteristic
(N=1,656)
medication (N=1,885)b
pc
Maternal education
<0.001
<12 years
54 (3.7)
89 (5.9)
12 years
789 (54.7)
906 (60.1)
>12 years
600 (41.6)
512 (34.0)
Paternal education
<12 years
12 years
>12 years

53 (3.7)
608 (42.1)
785 (54.3)

75 (4.9)
745 (48.8)
708 (46.3)

<0.001

Monthly family income
<1M KW
1–<2M KW
2–<3M KW
3–<4M KW
4–<5M KW
≥5M KW

65 (4.1)
237 (15.1)
510 (32.5)
367 (23.4)
243 (15.5)
147 (9.4)

146 (8.4)
328 (18.9)
551 (31.8)
380 (21.9)
184 (10.6)
145 (8.4)

<0.001

Maternal smoking
during pregnancy
Yes
No

5 (0.4)
1433 (99.7)

12 (0.8)
1513 (99.2)

Family history of ASD
Yes
No

33 (2.0)
1613 (98.0)

25 (1.3)
1843 (98.7)

0.145

0.122

Disease during
pregnancy
Yes
No

148 (11.1)
1183 (88.9)

116 (7.9)
1355 (92.1)

Child’s sex
Male
Female

808 (48.8)
848 (51.2)

969 (51.4)
916 (48.6)

68 (4.8)
1364 (95.3)

67 (4.4)
1441 (95.6)

Premature birth
Yes
No

0.003

0.121

0.692

6

Parity

1st child
2nd child
≥3rd child

<0.001
845 (54.7)
579 (37.5)
120 (7.7)

725 (42.5)
749 (43.9)
234 (13.7)

Gestational age at birth
<0.001
9 (0.6)
40 (2.3)
≤31 weeks
32-36 weeks
225 (14.0)
221 (12.7)
37-41 weeks
1171 (73.0)
1211 (69.6)
200 (12.5)
268 (15.4)
≥42 weeks
a. Values are N (%) for categorical variables.
b. Column percentages may not sum to 100 due to missing data and rounding.
c. p-values are for the chi-square test or Fisher’s exact test.
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Table 2. Description of the sample population, by prenatal medication (N=3,711).
Prenatal medication
N (%)a
Any medication
Yes
1656 (44.6)
No
1885 (50.8)
Hyperemesis
Yes
No

172 (4.6)
3369 (90.8)

Hypertension
Yes
No

9 (0.2)
3532 (95.2)

Folic acid
Yes
No

85 (2.2)
3459 (93.2)

Iron
Yes
No

1551 (41.8)
1990 (53.6)

Alternative
Yes
No

77 (2.1)
3464 (93.3)

Pain
Yes
No

32 (0.9)
3509 (94.6)

Prenatal vitamins
Yes
No

106 (2.9)
3435 (92.6)

Other
Yes
42 (1.1)
No
3669 (98.8)
a. Column percentages may not sum to 100 due to rounding and missing data
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Table 3. Associations between ASSQ and SRS measures and prenatal medication use.
No. (%) of Participants
Used any prenatal
Did not use any prenatal
medication
medication
Outcome measure
(N = 1,656)a
(N = 1,885)a
pb
ASSQ total score
0.919
High ASD
likelihood
80 (4.9)
94 (5.0)
(ASSQ ≥ 15)
Intermediate ASD
likelihood
(10 ≤  ASSQ < 15)
Low ASD
likelihood
(ASSQ < 10)
SRS T-score
High ASD
likelihood
(SRS ≥ 76)
Intermediate ASD
likelihood
(60 ≤  SRS < 76)

124 (7.5)

135 (7.2)

1445 (87.6)

1645 (87.8)
0.237

19 (1.2)

27 (1.5)

167 (10.2)

218 (11.7)

Low ASD
likelihood
1456 (88.7)
1612 (86.8)
(SRS < 60)
a. Column percentages may not sum to 100 due to missing data and rounding.
b. p-values are for the chi-square test.
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Table 4. Crude and adjusted effect of prenatal medication use on ASSQ and SRS scores,
ordinal logistic regression.
Odds Ratio (95% Confidence Interval)
Outcome measure
Used any prenatal
Did not use any prenatal
medication
medication
ASSQ total score
Crude
1.01 (0.83–1.24)
1.00
a
Adjusted
1.20 (0.95–1.51)
1.00
Adjustedb
1.04 (0.85–1.28)
1.00
SRS T-score
Crude
0.84 (0.69–1.03)
1.00
Adjustedc
0.98 (0.78–1.25)
1.00
d
Adjusted
0.89 (0.72–1.10)
1.00
a. Adjusted for child’s sex and maternal education.
b. Multiple imputation model; Adjusted for child’s sex and maternal education.
c. Adjusted for child’s sex, paternal education, and premature birth.
d. Multiple imputation model; Adjusted for child’s sex, paternal education, and premature
birth.
Table 5. Crude and adjusted effect of prenatal vitamin, folic acid, or iron supplement use
on ASSQ and SRS scores, binary logistic regression.
Odds Ratio (95% Confidence Interval)
Used prenatal vitamins,
Outcome measure
folic acid, or iron
Did not use medication
ASSQ total score ≥10
Crude
0.98 (0.79–1.22)
1.00
a
Adjusted
0.99 (0.80–1.22)
1.00
SRS T-score ≥60
Crude
0.72 (0.58–0.90)
b
Adjusted
0.87 (0.68–1.13)
a. Adjusted for child’s sex.
b. Adjusted for paternal education and premature birth.

1.00
1.00
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Table 6. Crude and adjusted effect of any prenatal medication use (excluding vitamins,
folic acid, or iron supplements) on ASSQ and SRS scores, binary logistic regression.
Odds Ratio (95% Confidence Interval)
Used medication other
than vitamins, folic acid,
Outcome measure
or iron
Did not use medication
ASSQ total score ≥10
Crude
1.72 (1.00–2.97)
1.00
Adjusteda
1.72 (1.00–2.97)
1.00
SRS T-score ≥60
Crude
1.33 (1.42–1.82)
Adjustedb
1.55 (0.79–3.02)
a. All covariates were removed during backward elimination.
b. Adjusted for child’s sex, paternal education, and premature birth.

1.00
1.00
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Table 7. Crude and adjusted effect of number of prenatal medications taken on ASSQ and SRS scores, binary
logistic regression.
Odds Ratio (95% Confidence Interval)
Outcome
Zero prenatal
1 prenatal
2 prenatal
3 prenatal
4+ prenatal
p for
measure
medications
medication
medications
medications
medications
trendc
ASSQ
0.352
score ≥10
Crude
1.00
0.99
1.15
0.90
1.80
(0.80–1.23)
(0.79–1.66)
(0.38–2.12)
(0.20–16.14)
Adjusteda
1.00
1.19
1.36
1.00
1.80
(0.93–1.52)
(0.91–2.06)
(0.39–2.57)
(0.19–16.92)
SRS Tscore ≥60
Crude

0.249
1.00

0.78
1.08
(0.63–0.98)
(0.75–1.56)
Adjustedb
1.00
0.91
1.29
(0.71–1.19)
(0.86–1.94)
a. Adjusted for child’s sex and maternal education.
b. Adjusted for child’s sex, paternal education, and premature birth.
c. Cochran-Armitage test for trend

0.98
(0.44–2.19)
1.25
(0.52–3.01)

1.65
(0.18–14.78)
1.70
(0.17–17.40)
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Introduction
Autism spectrum disorder is a complex neurodevelopmental disorder marked by
deficits in social communication, as well as in restrictive and repetitive behaviors (APA,
2013). The prevalence of ASD has risen dramatically in recent years. According to the
Centers for Disease Control and Prevention’s (CDC) Autism and Developmental
Disabilities Monitoring (ADDM) Network, analysis of data from 2010 reveals that ASD
affects 1 in 68 (~1.5%) children in the United States (Developmental, 2014). Results
from the National Survey of Children’s Health (NSCH) reveal that the parent-reported
prevalence of ASD in children ages 6 to 17 increased from 1.16% in 2007 to 2.00% in
2011–2012 (Blumberg et al., 2013). Observed increases in ASD prevalence have not
been restricted to the United States. Idring and colleagues (2014) investigated the
prevalence of ASD in the Stockholm Youth Cohort (SYC), finding a change in
prevalence among children ages 0 to 17 from 0.42% in 2001 to 1.44% in 2011. In
addition, ASD prevalence has been measured at greater than 2% in South Korean samples
(Kim et al., 2011).
ASD is thought to be among the most genetic of neuropsychiatric disorders
(Miles, 2011; O’Roak & State, 2008; Rutter et al., 1999). Early twin studies provided the
foundation for this notion, calculating the disorder’s heritability at above 90% and
demonstrating a large difference in concordance rate between monozygotic and dizygotic
twins (60%-90% vs. <5%; Rutter et al., 1999). The largest and most recent ASD twin
study, from a group in Sweden, has also supported the idea of a strongly genetic
component, calculating a relative recurrence risk (RRR) of ASD of 153.0 (95%
confidence interval [CI] 56.7–412.8) among monozygotic twins and observing an
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increasing RRR with increasing genetic relatedness (Sandin et al., 2014). However, to
date only 20% of all cases of ASD have been explained by inherited genetic variants
(Miles, 2011). The Swedish twin study recently estimated the heritability—the proportion
of phenotypic variability attributable to genetic variation—of ASD to be 0.50 (95% CI
0.45–0.56), and the contribution of non-shared environmental influence was estimated at
0.50 (95% CI 0.44–0.55). Thus, while the cause of ASD is likely to have a strongly
genetic component, there is still a possibility that environmental factors acting directly or
through gene-environment interactions may contribute substantially to ASD etiology.
Over the years, several studies have attempted to elucidate the relationship
between medication use during pregnancy and development of autism in offspring. In the
first meta-analysis of the relationship between prenatal factors and ASD risk, Gardener
and colleagues (2009) identified fifteen studies that examined prenatal medication use
and determined that maternal use of any medication during pregnancy was associated
with a 46% increased risk of ASD (95% CI 8%–96%). Maimburg and Vaeth (2006)
conducted a case-control study examining the associations between a variety of
exposures and infantile ASD. Data on prenatal medication use was obtained from Danish
medical birth records for approximately 460 cases and 460 controls. After adjusting for
parental ages, maternal citizenship, birth weight, gestational age, Apgar score, and birth
defects, the authors found that children of mothers who took medications during
pregnancy had an odds ratio (OR) of 1.5 (95% CI 1.1–2.1) compared to children of
mothers who did not take medications, although the authors did not specify which classes
of medication were included in their analyses (Maimburg & Vaeth, 2006). In contrast to
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these studies, an earlier review of seven studies did not report an association between
prenatal medication use and autism or autistic traits (Kolevzon et al., 2007).
Other studies have focused on various types of medications and supplements. In a
rodent model of autism, a Korean group demonstrated that prenatal administration of
Korean red ginseng extract—a traditional Korean medicine—inhibited valproate-induced
hyperactivity and decreased sociability in the offspring (Kim et al., 2013). Several studies
have investigated associations between prenatal folic acid use and ASD. Steenweg-de
Graaff and colleagues (2014) observed in a prospective study that maternal folate plasma
concentration during pregnancy was not associated with autistic traits in children.
However, this group also observed that children of mothers who used prenatal folic acid
supplements had lower autistic traits scores, as measured by the Social Responsiveness
Scale (SRS), compared to children of mothers who did not use such supplements
(p<0.001; Steenweg-de Graaff et al., 2014). In an analysis of over 97,000 individuals
enrolled in the Norwegian Mother and Child Cohort (MoBa), Surén and colleagues
(2013) examined use of folic acid supplements from four weeks before to eight weeks
after the start of pregnancy. Exposure assessment occurred via a postal questionnaire
administered at gestation week 18 and a food frequency questionnaire administered at
gestation week 22. After adjusting for year of birth, maternal education level, and parity,
the authors found that children of mothers who took folic acid had decreased odds of
being autistic compared to children of mothers who did not take folic acid (OR 0.61, 95%
CI 0.41–0.90; Surén et al., 2013). Schmidt et al. (2012) examined folic acid as an
exposure in an analysis of participants from the Childhood Autism Risks from Genetics
and Environment (CHARGE) study. Mean folic acid intake was significantly greater in
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the first month of pregnancy for typically developing children (N=278) compared to
children with ASD (N=429). In comparison with children whose mothers reported taking
<600 𝜇g/day of folic acid, children whose mothers took ≥600 𝜇g/day had an ASD OR of
0.62 (95% CI 0.42–0.92). Folic acid intake was then categorized into quintiles, and a
significant trend (p=0.01) was observed for decreasing risk of ASD as folic acid intake
increased, controlling for maternal education level and child’s birth year. However, this
trend was rendered non-significant after also adjusting for intake of vitamins A, B6, C,
and D.
The CHARGE study has also yielded insight into the relationship between
prenatal vitamin use and ASD (Schmidt et al., 2011). In a 2011 study, prenatal vitamin
exposure was assessed retrospectively through phone interviews. After adjusting for
maternal education and the child’s birth year, children of women who used prenatal
vitamins three months before pregnancy through one month after conception had reduced
odds of ASD compared to children whose mothers did not use prenatal vitamins during
this time period (OR 0.62, 95% CI 0.42–0.93). In an analysis of data from the Health
Outcomes and Measures of the Environment (HOME) study, mothers were interviewed
during pregnancy about second trimester prenatal vitamin use, and autistic behaviors
were later measured in enrolled children at ages 4 and 5 using the SRS (Braun et al.,
2014). Compared to children of women who reported using prenatal vitamins weekly or
daily, children of women who reported using them never or rarely had reduced odds of
having a T-score ≥60 (reflecting autistic behaviors of mild to moderate severity) on the
SRS after adjusting for a variety of prenatal and demographic variables.
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Finally, prenatal use of antidepressant and antiepileptic drugs has received
increased attention as an exposure that may be related to autism. A prospective study
conducted with participants in the MoBa cohort reported that children exposed to
antiepileptic drugs in utero yielded a 3.4-fold increased risk (95% CI 1.6–7.0) of the child
having autistic traits, compared to unexposed children, as measured by the Social
Communication Questionnaire (SCQ) and adjusting for several maternal and child factors
(Veiby et al., 2013). Croen and colleagues (2011) observed that children of mothers in a
Northern California population who took selective serotonin reuptake inhibitors (SSRIs)
during the first trimester had a 3.5-fold increased risk (95% CI 1.5–7.9) of ASD
compared to unexposed children after controlling for age, race, education, and other
factors. Highlighting the lack of consensus regarding the role played by medication use in
the etiology of ASD, numerous studies have failed to find an association between
prenatal antidepressant use and ASD, some employing the same cohorts as studies that
reported positive associations (Hviid et al., 2013; Sørensen et al., 2013; Clements et al.,
2014).
Previous studies have yielded mixed findings regarding the association between
prenatal medication use and ASD. Different methodologies have been used to assess
differing exposures and outcomes in various populations. Thus, there remains a need for
further investigation to build upon these earlier investigations in determining whether
prenatal use of medications and supplements contributes to risk for ASD. If prenatal
medication use were ultimately shown to impart ASD risk in several disparate
populations, then there would be strong evidence for a true association between
medication use and ASD occurrence. Further, if such an association exists, then there are
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two important opportunities: 1) a potential role for gene-environment interactions (GxE)
or fetal programming in the etiology of ASD, and 2) the possibility of a preventive
intervention that alters the use of these medications during pregnancy. GxE are defined
by genetic differences in vulnerability to specific environmental factors that contribute to
a phenotype (Kim & Leventhal, 2015), while fetal programming of adult health states
takes place when normal patterns of fetal growth are disrupted due to unfavorable
conditions in utero (Pollard, 2007). Both of these influences on adult phenotype are
important avenues through which medication use may affect autism risk if a true
association exists.
This study is intended to inform future research investigating environmental
factors in utero that may play a role in the etiology of autism. Equipped with a large
sample size and the ability to incorporate a number of potential confounding variables,
the present study is, to our knowledge, the first analysis of the association between
prenatal medication use and autistic traits in a South Korean cohort.
Materials and Methods
Study population
This study is a secondary analysis of de-identified data from the Children’s Health
and Environmental Research (CHEER) study, an effort to examine associations between
environmental agents and health outcomes affecting South Korean children. The CHEER
study is sponsored by the Korean Ministry of the Environment, and a detailed description
of this research effort is found in Ha et al., 2009. Briefly, from 2005 to 2007, 6,722 fiveto fourteen-year-old students from 22 public schools in 10 South Korean locations (3
metropolitan, 4 industrialized, and 3 rural) were recruited for evaluation in the ongoing
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CHEER study. From the original cohort, 5,293 students (79%) completed follow-up
evaluations in 2007 and 2008, during which environmental exposure data were collected
and blood and urine testing, perinatal risk evaluations, and physical exams were
performed. The 40 cc of blood collected from each individual was stored at -70oC in the
biorepository at Dankook University. This follow-up sample was 51.5% male and had a
mean age of 7.3±1.0 years. Of this sample, 3,804 agreed to participate in the CHEER
gene-environment interaction study. After excluding 93 participants who self-reported
use of unspecified “weight gain” medications, these individuals formed our study sample
for the present analyses.
Exposure ascertainment
The primary exposure measure was use of any of seven classes of medication
during pregnancy. The medications included were folic acid, hypertension medication,
hyperemesis medication, iron supplements, alternative medicines, pain medication, or
prenatal vitamins. In separate survey items, mothers of participating children were asked
to recall whether they had taken these medications during pregnancy. Use of any prenatal
medication was defined as responding “yes” to any of these items or writing in a different
medication in a free-response field.
Outcome ascertainment
The two main outcome variables were parent-rated Autism Spectrum Screening
Questionnaire (ASSQ) total score and parent-rated Social Responsiveness Scale (SRS) Tscore. The ASSQ is a parent- or teacher-completed checklist useful for identification of
Asperger’s and other high-functioning ASD in children and adolescents with normal
intelligence or mild intellectual disability (Ehlers et al., 1999). The questionnaire consists
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of 27 items, each inquiring whether the child stands out as different from other children
of his or her age in some way. Responses are rated on a scale from 0 (no) to 2 (yes). For
the present analysis, it was decided that a cutoff score of ≥15 was reasonable for high
likelihood of ASD based on the notion that this score represented 76% sensitivity and
81% specificity for detecting ASD (Ehlers et al., 1999). Consequently, ASSQ scores in
the range of 10 to 14 were selected to indicate social impairment as a proxy for
intermediate likelihood of having ASD. While the ASSQ has yet to be validated in South
Korean populations, it has been translated into Korean and used in previous autism
research in that country (Kim et al., 2011).
The SRS is a parent- or teacher-completed questionnaire designed to assess a
child’s ability to engage in reciprocal social interaction (Constantino et al., 2003). The
questionnaire consists of 65 items, each rating an observed aspect of social behavior on a
numeric scale from 1 (never true) to 4 (almost always true). Interpretation is based on a
single score reflecting the sum of all 65 responses, which is converted to a standardized
T-score. A T-score between 60 and 75 places the child within the mild to moderate range,
suggesting that the child has mild or high-functioning ASD. A T-score of 76 or higher
places the child within the severe range, as these scores are strongly associated with an
ASD diagnosis (Constantino & Gruber, 2005). The CHEER study employed the Korean
version of the SRS.
Statistical analysis
All statistical analyses were conducted using SAS, version 9.4 software via the
SAS Studio interface, version 3.3 (SAS Institute Inc., Cary, NC). Crude associations
between the exposure of interest and covariates were conducted with the chi-square test.
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The crude and adjusted relationships between prenatal use of any medication and ASSQ
and SRS scores were examined using ordinal logistic regression models. The following
covariates were examined as potential confounders of these associations: parent-reported
maternal education, paternal education, monthly family income, maternal smoking during
pregnancy, family history of ASD, maternal disease during pregnancy, child’s sex,
premature birth, gestational age at birth, and parity. The majority of these covariates were
included on the basis of having been incorporated into previous analyses of relationships
between prenatal medication use and ASD (Braun et al., 2014; Schmidt et al., 2011;
Schmidt et al., 2012; Surén et al., 2013). Disease during pregnancy was defined as having
any of gestational diabetes, pregnancy-related hypertension, pre-eclampsia, thyroid
disease, appendicitis, asthma, atopy, or any self-reported disease during the prenatal
period. We arrived at the final logistic regression models via backward elimination of
covariates. Covariates that remained significant at the 0.05 level for the Wald chi-square
test were retained. In crude and adjusted analyses, complete case analysis was performed.
Power was greater than 90% to detect a true odds ratio of 1.5 (Appendix). Sensitivity
analyses using multiple imputation were constructed to assess the impact of missing data.
In secondary analyses, the crude and adjusted impact of folic acid, prenatal vitamin, or
iron supplement use vs. medication non-use, as well as the impact of the number of
medications taken, were assessed using binary logistic regression models.
Results
Study participants
This study sample consisted of 3,711 mother-child pairs, which is approximately
55% of the original CHEER cohort. Data on the primary exposure of prenatal use of any
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medication were missing for 170 (4.6%) participants. Mothers who took any prenatal
medication tended to have had a disease during pregnancy, and they also tended to be
more highly educated and wealthier (Table 1). Compared to mothers who took prenatal
medications, mothers who did not take any prenatal medications did not differ
significantly with respect to smoking status, family history of ASD, giving birth
prematurely, or child’s sex.
Prenatal medication intake
Use of any medication during pregnancy was reported by 1,656 mothers (44.6%)
in the study sample (Table 2). Iron supplements were the most common medication
reported, with over 40% of prenatal medication users reporting iron supplement use. By
contrast, hypertension medication use was least prevalent in the sample, with only 0.2%
of those who took medications reporting its use. As shown in Table 3, prenatal use of any
medication did not have a significant association with either ASSQ total score or SRS Tscore, as measured by the chi-square test. The distribution of ASD likelihood as
measured by both parent-rated ASSQ and parent-rated SRS was similar between children
of mothers who did and did not use medications during pregnancy.
The crude and adjusted effects of prenatal medication use on ASSQ and SRS
scores are shown in Table 4. In the unadjusted analysis, use of any prenatal medication
was not predictive of an increased ASSQ score compared to non-use of prenatal
medication. After adjusting for child’s sex and maternal education, the OR for this
association increased slightly but remained non-significant at 0.05 level (OR 1.20, 95%
CI 0.95–1.51). Similarly, use of any prenatal medication was not predictive of an
increased SRS score compared to non-use of prenatal medications in the unadjusted
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analysis. After adjusting for child’s sex, paternal education, and premature birth, the
association remained non-significant (OR 0.98, 95% CI 0.78–1.25). Sensitivity analyses
with imputed values for all variables in the adjusted analyses were also non-significant,
although these effect estimates did not pass the score test for the proportional odds
assumption and may thus be inaccurate estimates.
In the secondary analyses, children of mothers who used prenatal vitamins, folic
acid, or iron supplements were no more likely to have an ASSQ score of 10 or greater
compared to children of mothers who did not report prenatal medication use (Table 5; OR
0.99, 95% CI 0.80–1.22). Despite the observation of a protective effect in the crude
analysis, children of mothers who took prenatal vitamins, folic acid, or iron supplements
were not significantly more likely to have an SRS T-score of 60 or more in comparison to
children of mothers who did not use medications in the adjusted analysis (OR 0.87, 95%
CI 0.68–1.13). Conversely, in crude analyses, children of women who used any
medication other than vitamins, folic acid, or iron supplements were more likely to have
both an ASSQ score ≥10 and an SRS T-score ≥60 (Table 6). Attempts to adjust for
covariates did not alter the ASSQ OR, but the SRS OR was rendered non-significant
following adjustment for child’s sex, paternal education, and premature birth. Finally, no
dose-response relationship between number of medications taken and risk of autistic
behaviors was observed (Table 7). One odds ratio in the crude analysis was marginally
significant at the 0.05 level, but no effect estimates in the adjusted analyses were
significant. Slight dose-response trends were observed correlating higher scores of
autistic behavior with increasing number of medications taken, particularly in the SRS
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analysis, but these too were deemed non-significant by the Cochran-Armitage test for
trend.
Discussion
Prenatal medication intake
In this study of a South Korean cohort, no significant associations were found
between prenatal medication use and ASSQ total score, as well as between prenatal
medication use and SRS T-score. To our knowledge, this is the first study that has
investigated these associations in a South Korean population. Assuming that the
prevalence of autism in this Korean population is similar to that calculated by Kim and
colleagues (2.64%), this study had sufficient power to detect an OR of 1.5 for children of
exposed vs. unexposed mothers (Appendix). However, a much larger study sample would
be necessary to detect a significant effect estimate if the true OR is more moderate than
1.5. An OR of 1.5 was chosen for our power calculations based on the ORs of 1.46 and
1.50 observed by Gardener et al. (2009) and Maimburg & Vaeth (2006), respectively, in
their assessments of the relationship between any prenatal medication use and ASD.
Sensitivity analyses employing multiple imputation of the variables included in the
adjusted analysis did not substantially impact the ORs reported in Table 4.
Several of the covariates used in the main analyses had non-trivial amounts of
missing data. For the adjusted ASSQ analysis in Table 4, 799 (20.9%) subjects were
excluded due to missing data, while 873 (23.5%) subjects were excluded from the
adjusted SRS analysis. Assuming non-differential misclassification of missingness, this
phenomenon would be expected to bias the results toward the null, which could explain
in part our non-significant effect estimates. Additionally, if mothers who took prenatal
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medications are biologically different from mothers who did not take such medications,
our results could be impacted by confounding by indication. In other words, the child’s
risk of autism could be influenced by the conditions that caused the mothers to take
medications, rather than the medications themselves. Small numbers of subjects reporting
certain medications, such as hypertension and pain medications, necessitated the use of a
composite primary exposure variable and precluded substantial secondary analyses
investigating medication subtypes. If such subgroup analyses had been possible, it might
have been clearer as to which medications may impart the greatest risk of autism to
offspring in this population.
Previous studies have suggested that use of prenatal vitamins and folate may
confer protective effects against autism development to the fetus (Braun et al., 2014;
Schmidt et al., 2011; Schmidt et al., 2012). Our secondary analyses of this relationship
did not agree with these studies, as we observed in our adjusted analyses no significant
association between maternal prenatal vitamin, folic acid, or iron supplement use and
both outcome measures (Table 5). Iron supplements were included in this composite
exposure variable because, like prenatal vitamins and folic acid, these supplements are
taken as part of routine prenatal care rather than for a specific condition requiring
treatment. These analyses were also impacted by missing data to roughly the same extent
as the primary analyses. For the adjusted ASSQ analysis in Table 5, 472 (12.7%) subjects
were excluded due to missing data, and 1,107 (29.8%) subjects were excluded from the
adjusted SRS analysis. The analyses in Table 6 show the converse of those in Table 5.
Use of any medication other than vitamins, folic acid, or iron supplements was shown to
be borderline significant with an increased ASSQ score, while a non-significant OR was
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observed in the SRS analysis. We hypothesized that, in contrast to the medications in
Table 5, these medications might place children at increased risk of autistic behaviors.
While we did observe ORs above 1.0, they were not significant at the 0.05 level. It is
possible that, with a larger sample size, a significant effect might have been observed.
In the final secondary analyses, no significant trend relating increased prenatal
medication intake to higher ASSQ and SRS scores was observed (Table 7). The wide CIs
for some cells are indicative of the imprecision of these calculations, as cell sizes for
those reporting the highest usage of medication were small. Few people reported taking
more than four medications during pregnancy, so it was necessary to collapse these
individuals into a single category of high medication intake so that the cell sizes would be
large enough to conduct these analyses. Similarly, binary logistic regression was chosen
over ordinal logistic regression for all secondary analyses, as the cell sizes would have
been too small to permit meaningful calculations.
Study strengths and limitations
The large sample size in this study allowed for precise effect estimates in the
primary analyses. Also, substantial covariate data allowed for the inclusion of numerous
potential confounders in the adjusted analyses. Use of multiple measurements of autistic
behaviors permitted us to examine the effect of medication use on disparate components
of the autism phenotype. However, retrospective self-report of exposure information
invites the possibility of recall bias. Mothers in this study were asked to provide exposure
information from several years in the past, and recall accuracy was likely an issue for
many participants. In some cases, mothers could have been recalling exposure
information after their children had already been formally diagnosed with ASD, and these
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mothers might have been more inclined than mothers of children without autism to report
prenatal medication use, thinking it a potential cause of autism. At the same time, the
total number of children scoring in the high-risk ranges of the ASSQ and SRS is small, so
any recall bias is likely to be non-differential, skewing our results toward the null. The
results in our analyses were also plagued by substantial missing data for several
covariates. For almost all of our complete case analyses, more than one-fifth of all
subjects were excluded due to missing data. These missing data impair our ability to
generalize the results of this study to the rest of the CHEER cohort, as our study sample
may not be wholly representative of the study population.
We are also limited by a lack of information on the frequency and dosage of
prenatal medications to which women in the cohort were exposed. It is possible that
prenatal medication use could confer autism risk only during particular stages of
pregnancy, and previous studies have observed significant associations between use of
specific medications during particular trimesters and ASD risk (Croen et al., 2011;
Gidaya et al., 2014). However, women in the current study only self-reported any use of
prenatal medications rather than use during specific intervals, so stratification by
trimester was not possible. The lack of dosage information precluded the ability to test
whether higher doses of specific medications might confer higher risk of ASD to the
offspring. For almost all of the seven broad classes of medication examined in this study,
the prevalence of use was too small to permit subgroup analyses that would have allowed
us to examine the separate effects of different classes of medication. It is likely that the
dosage of specific types of medication taken during pregnancy, rather than the total
number of different medications taken, is of great importance in elucidating the
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relationship between medication use and ASD risk, yet we were unable to investigate this
area further in this study. This consideration is especially important in relation to
potential opportunities for GxE as well as fetal programming. Different subtypes of
prenatal medication, and even different medications within those subtypes, can exert
disparate effects on the developing fetus. An inability to study medication subtypes
makes it difficult to form plausible biological mechanisms for the potential effect of
prenatal medications on autism development via GxE or fetal programming.
Although a number of previous studies have examined use of any prenatal
medication as a risk factor for ASD (Gardener et al., 2009; Maimburg & Vaeth, 2006),
not all of these studies specified the precise subclasses of medications that were included
under the catch-all of “any medication use.” This lack of detailed information makes it
difficult to directly compare the results of this study with previous work. For example,
the CHEER cohort did not contain information about use of psychiatric medication such
as antidepressants, whereas Gardener and colleagues in their review identified this
subclass of medications as one that might put children at an increased risk of ASD
compared to just “any medication use” (Gardener et al., 2009).
Finally, outcome assessment in this sample population was conducted using tools
that screen for autistic behaviors rather than those that form the gold standard in autism
diagnosis. Our analysis thus assessed the risk of having a high score on either the ASSQ
or SRS rather than receiving a clinical ASD diagnosis via the Autism Diagnostic
Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS).

28
Conclusions
Though subject to various limitations as noted above, our data do not suggest an
association between prenatal medication use and risk of autistic behaviors in this South
Korean population. Given the disagreement between these results and those of previous
studies, especially with regard to prenatal vitamin and folic acid use, further study with
improved exposure assessment is warranted in order to clarify any relationship between
prenatal medication use and autism that may exist. Such a relationship would provide
evidence for an environmental contribution to autism risk, which could enable an avenue
for intervention aimed at reducing autism risk in the population.
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Appendix

Ordinal logistic regression power calculations
Adapted from:
Whitehead, J. (1993). Sample size calculations for ordered categorical data. Statistics in Medicine, 12(24),
2257–2271. doi:10.1002/sim.4780122404

OR of 1.5
Table A1.
No prenatal meds

C1 – low likelihood
ASD (ASSQ or
SRS)
p(iC)
0.9236
Q(iC)
0.9236
a. Prevalence estimate from Kim et al., 2011

C2 – intermediate
likelihood ASD
(ASSQ or SRS)
0.05
0.9736

C3 – high likelihood
ASD (ASSQ or
SRS)
0.0264a
1

Fig. A1. Equation for ln(OR), from Whitehead, 1993
𝜃! = ln

0.9604(1 − 0.9736)
=    −0.419
0.9736(1 − 0.9604)

Fig. A2. Equation for cumulative probabilities of exposed group, from Whitehead, 1993
𝑄!!" =

0.9236
= 0.88828
0.9236 + 1 − 0.9236 𝑒 !.!"#

Table A2.
Prenatal meds
C1 – low likelihood C2 – int. likelihood
C3 – high likelihood
p(iER)
0.88828
0.07212
0.0396a
Q(iER)
0.88828
0.9604
1
a. Assumes that, if prenatal use of any medication does increase the likelihood of having
a child with ASD, among those exposed to any medication, probability of being in high
likelihood group is 1.5 times that of the unexposed group.
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Table A3.
C1 – low likelihood
C2 – int. likelihood
C3 – high likelihood
!.!!!"!!!.!"#$
!.!"!!.!"#$#
!.!"#$!!.!"#$
𝑝!
= 0.9059
= 0.1221
= 0.0660
!
!
!

Fig. A3. Equation for total N required
Where A = allocation ratio = Nexposed:Nunexposed = 1
80% power
𝑁=

3(1 + 1)! (1.96 + 0.84)!
= 2105.9 = 2106 = 1053  𝑝𝑒𝑟  𝑔𝑟𝑜𝑢𝑝
−0.419 ! (0.254)

90% power
𝑁=

3(1 + 1)! (1.96 + 1.28)!
= 2824.9 = 2825 = 1413  𝑝𝑒𝑟  𝑔𝑟𝑜𝑢𝑝
−0.419 ! (0.254)

OR of 1.25
Table A4.
No prenatal meds

C1 – low likelihood
ASD (ASSQ or
SRS)
p(iC)
0.9236
Q(iC)
0.9236
a. Prevalence estimate from Kim et al., 2011

C2 – intermediate
likelihood ASD
(ASSQ or SRS)
0.05
0.9736

C3 – high likelihood
ASD (ASSQ or
SRS)
0.0264a
1

Fig. A4. Equation for ln(OR), from Whitehead, 1993
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𝜃! = ln

0.967(1 − 0.9736)
=    −0.230
0.9736(1 − 0.967)

Fig. A5. Equation for cumulative probabilities of exposed group, from Whitehead, 1993
𝑄!!" =

0.9236
= 0.9057
0.9236 + 1 − 0.9236 𝑒 !.!"#

Table A5.
Prenatal meds
C1 – low likelihood C2 – int. likelihood
C3 – high likelihood
p(iER)
0.9057
0.0613
0.033a
Q(iER)
0.9057
0.967
1
a. Assumes that, if prenatal use of any medication does increase the likelihood of having
a child with ASD, among those exposed to any medication, probability of being in high
likelihood group is 1.25 times that of the unexposed group.
Table A6.
C1 – low likelihood
C2 – int. likelihood
C3 – high likelihood
!.!"#$!!.!"#$
!.!"!!.!"#$
!.!"#$!!.!""
𝑝!
= 0.9147
= 0.05565
= 0.0297
!
!
!

Fig. A6. Equation for total N required
Where A = allocation ratio = Nexposed:Nunexposed = 1
𝑁=

3(1 + 1)! (1.96 + 0.84)!
= 7585 = 3793  𝑝𝑒𝑟  𝑔𝑟𝑜𝑢𝑝
−0.230 ! (0.234)

